Harsha Mirchandani
FSA, MAAA
Senior Consulting Actuary
New York, NY, US
Harsha Mirchandani is a senior consulting actuary with the New York office of Milliman. She joined the firm in 2016.
Experience
Harsha has provided consulting services to a broad range of clients, including health plans, provider groups, hospital systems, pharmaceutical companies, and other healthcare providers.
Harsha has extensive experience with the following:
- Harsha has extensive experience with the following:
- Alternative payment model design, implementation, and reconciliation
- Value-based contracting design and analytics
- Claims-based analytics and benchmarking
- Advanced data visualization using business intelligence software (e.g., PowerBI, Qlik)
Prior to joining Milliman, Harsha worked in pharmaceutical and medical device marketing.
Professional Designations
- Fellow, Society of Actuaries
- Member, American Academy of Actuaries
Education
- BS, Chemical Engineering with Mathematics Minor, Tufts University
Publications
Read their latest work
Article
2024 Milliman Qualified Entity (QE) Report
19 July 2024 - by Carol Bazell, Cherie Dodge, Harsha Mirchandani, Hope Norris, Julia Weber
Created for the Centers for Medicare & Medicaid Services, Milliman’s health equity tool explores how healthcare system performance relates to population characteristics such as race and ethnicity.
Article
Methodology review of Stork Club’s assisted reproductive technology performance measure comparison study
15 March 2024 - by Harsha Mirchandani, Brittany Ryan, Carol Bazell
We examine Stork Club’s methodology for assessing Assisted Reproductive Technology performance measures.
Article
Summary of The U.S. Playbook to Address Social Determinants of Health
11 December 2023 - by Bridget Darby, Harsha Mirchandani, Shelley Moss
We summarize of the pillars contained in the White House’s "U.S. Playbook to Address Social Determinants of Health" and discuss implications for stakeholders.
Article
2023 Milliman Qualified Entity (QE) Report
24 July 2023 - by Carol Bazell, Cherie Dodge, Harsha Mirchandani
Created for the Centers for Medicare & Medicaid Services, Milliman’s health equity tool explores how healthcare system performance relates to population characteristics such as race and ethnicity.
Article
Treatment patterns for generalized anxiety disorder and insomnia in Medicare fee-for-service
28 March 2023 - by Carol Bazell, Harsha Mirchandani, Pamela M. Pelizzari, Katherine Brinkers
Insomnia and generalized anxiety disorder are common mental health conditions in the Medicare population.
Article
Enhancing Oncology Model (EOM): OCM “2.0”
28 July 2022 - by Harsha Mirchandani, Noah Champagne, Pamela M. Pelizzari
This article highlights considerations for providers interested in voluntary enhanced oncology model, which builds on concepts of a recently completed CMMI model designed to transform oncology care while reducing spending under Medicare fee-for-service.
Article
Strategy considerations for effectively entering the Medicare Advantage market
14 July 2022 - by Eric Buzby, Harsha Mirchandani, Jared Hirsch
Six important topics insurers should consider as they contemplate entering the Medicare Advantage market.
Article
Healthcare cost journey for survivors of firearm injuries
11 July 2022 - by Samantha Tomicki, Harsha Mirchandani, Rebecca L. Johnson
Given the medical costs of nonfatal firearm injuries, healthcare stakeholders have an interest in supporting further research to mitigate firearm injury risk
Article
Racial disparities in preventive services for Medicare FFS beneficiaries with type 2 diabetes
19 February 2021 - by Harsha Mirchandani, Samantha Tomicki, Rebecca Smith, Rebecca L. Johnson, Sally Maraldo, Andrew Yang
We describe significant racial disparities in access to preventive diabetes care.
Article
A claims-based analysis of sickle cell disease: Prevalence, disease complications, and costs
10 October 2019 - by Carol Bazell, Gabriela Dieguez, Christine Ferro, Harsha Mirchandani
This research report uses real-world medical and pharmacy claims data for sickle cell disease patients covered either by commercial insurance or managed Medicaid to develop relevant diagnosis, utilization, and cost metrics by payer type.